Compare Funko Inc (FNKO) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FNKO trades at $6.35, down 1.7% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% year-over-year, and raised EBITDA guidance to $105 million. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 19% upside potential from current levels.

Investment outlook remains cautiously optimistic as FNKO demonstrates operational improvements with margin expansion and debt reduction. Key risks include negative net income margins, volatile cash flow patterns, and competitive pressures in the collectibles market. The stock offers value with a low P/S ratio of 0.39x and attractive EV/EBITDA of 6.84x, but requires sustained profitability to justify further appreciation.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.